Annual EBIT
-$515.29 M
-$57.13 M-12.47%
December 31, 2023
Summary
- As of February 7, 2025, NTLA annual earnings before interest & taxes is -$515.29 million, with the most recent change of -$57.13 million (-12.47%) on December 31, 2023.
- During the last 3 years, NTLA annual EBIT has fallen by -$378.71 million (-277.27%).
- NTLA annual EBIT is now -3742.87% below its all-time high of -$13.41 million, reached on December 31, 2015.
Performance
NTLA EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$144.77 M
-$5.73 M-4.12%
September 30, 2024
Summary
- As of February 7, 2025, NTLA quarterly earnings before interest & taxes is -$144.77 million, with the most recent change of -$5.73 million (-4.12%) on September 30, 2024.
- Over the past year, NTLA quarterly EBIT has dropped by -$13.66 million (-10.42%).
- NTLA quarterly EBIT is now -12014.64% below its all-time high of -$1.20 million, reached on March 31, 2015.
Performance
NTLA Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$537.71 M
-$13.66 M-2.61%
September 30, 2024
Summary
- As of February 7, 2025, NTLA TTM earnings before interest & taxes is -$537.71 million, with the most recent change of -$13.66 million (-2.61%) on September 30, 2024.
- Over the past year, NTLA TTM EBIT has dropped by -$52.22 million (-10.76%).
- NTLA TTM EBIT is now -44896.49% below its all-time high of -$1.20 million, reached on March 31, 2015.
Performance
NTLA TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
NTLA EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -12.5% | -10.4% | -10.8% |
| 3 y3 years | -277.3% | -101.1% | -133.9% |
| 5 y5 years | -467.1% | -471.6% | -405.5% |
NTLA EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -92.4% | at low | -80.0% | at low | -100.8% | at low |
| 5 y | 5-year | -384.4% | at low | -415.2% | at low | -405.5% | at low |
| alltime | all time | -3742.9% | at low | <-9999.0% | at low | <-9999.0% | at low |
Intellia Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$144.77 M(+4.1%) | -$537.71 M(+2.6%) |
| Jun 2024 | - | -$139.04 M(+22.0%) | -$524.04 M(+1.3%) |
| Mar 2024 | - | -$114.00 M(-18.5%) | -$517.34 M(+0.4%) |
| Dec 2023 | -$515.29 M(+12.5%) | -$139.89 M(+6.7%) | -$515.29 M(+6.1%) |
| Sep 2023 | - | -$131.11 M(-0.9%) | -$485.49 M(+5.6%) |
| Jun 2023 | - | -$132.33 M(+18.2%) | -$459.91 M(+8.0%) |
| Mar 2023 | - | -$111.96 M(+1.7%) | -$425.88 M(-7.0%) |
| Dec 2022 | -$458.16 M(+71.1%) | -$110.09 M(+4.3%) | -$458.16 M(+6.9%) |
| Sep 2022 | - | -$105.53 M(+7.4%) | -$428.49 M(+8.5%) |
| Jun 2022 | - | -$98.30 M(-31.9%) | -$394.95 M(+8.0%) |
| Mar 2022 | - | -$144.25 M(+79.4%) | -$365.67 M(+36.5%) |
| Dec 2021 | -$267.85 M(+96.1%) | -$80.42 M(+11.7%) | -$267.85 M(+16.5%) |
| Sep 2021 | - | -$71.99 M(+4.3%) | -$229.83 M(+23.6%) |
| Jun 2021 | - | -$69.02 M(+48.7%) | -$185.94 M(+24.0%) |
| Mar 2021 | - | -$46.42 M(+9.5%) | -$149.96 M(+9.8%) |
| Dec 2020 | -$136.58 M(+28.4%) | -$42.40 M(+50.9%) | -$136.58 M(+10.2%) |
| Sep 2020 | - | -$28.10 M(-14.9%) | -$123.95 M(+2.3%) |
| Jun 2020 | - | -$33.03 M(-0.0%) | -$121.18 M(+4.8%) |
| Mar 2020 | - | -$33.05 M(+11.0%) | -$115.61 M(+8.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$106.37 M(+17.1%) | -$29.77 M(+17.5%) | -$106.37 M(+9.3%) |
| Sep 2019 | - | -$25.33 M(-7.8%) | -$97.34 M(+1.3%) |
| Jun 2019 | - | -$27.46 M(+15.3%) | -$96.11 M(+4.2%) |
| Mar 2019 | - | -$23.81 M(+14.8%) | -$92.25 M(+1.5%) |
| Dec 2018 | -$90.87 M(+30.6%) | -$20.75 M(-13.9%) | -$90.87 M(-4.2%) |
| Sep 2018 | - | -$24.10 M(+2.1%) | -$94.84 M(+9.5%) |
| Jun 2018 | - | -$23.59 M(+5.2%) | -$86.61 M(+9.6%) |
| Mar 2018 | - | -$22.43 M(-9.2%) | -$79.04 M(+13.6%) |
| Dec 2017 | -$69.56 M(+116.3%) | -$24.71 M(+55.7%) | -$69.56 M(+25.0%) |
| Sep 2017 | - | -$15.88 M(-0.9%) | -$55.66 M(+17.2%) |
| Jun 2017 | - | -$16.02 M(+23.7%) | -$47.48 M(+23.6%) |
| Mar 2017 | - | -$12.95 M(+19.6%) | -$38.41 M(+19.4%) |
| Dec 2016 | -$32.16 M(+139.8%) | -$10.82 M(+40.6%) | -$32.16 M(+19.9%) |
| Sep 2016 | - | -$7.70 M(+10.8%) | -$26.83 M(+19.6%) |
| Jun 2016 | - | -$6.95 M(+3.8%) | -$22.43 M(+18.6%) |
| Mar 2016 | - | -$6.69 M(+21.9%) | -$18.91 M(+41.0%) |
| Dec 2015 | -$13.41 M | -$5.49 M(+66.3%) | -$13.41 M(+69.3%) |
| Sep 2015 | - | -$3.30 M(-3.5%) | -$7.92 M(+71.5%) |
| Jun 2015 | - | -$3.42 M(+186.4%) | -$4.62 M(+286.4%) |
| Mar 2015 | - | -$1.20 M | -$1.20 M |
FAQ
- What is Intellia Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Intellia Therapeutics?
- What is Intellia Therapeutics annual EBIT year-on-year change?
- What is Intellia Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly EBIT year-on-year change?
- What is Intellia Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Intellia Therapeutics?
- What is Intellia Therapeutics TTM EBIT year-on-year change?
What is Intellia Therapeutics annual earnings before interest & taxes?
The current annual EBIT of NTLA is -$515.29 M
What is the all time high annual EBIT for Intellia Therapeutics?
Intellia Therapeutics all-time high annual earnings before interest & taxes is -$13.41 M
What is Intellia Therapeutics annual EBIT year-on-year change?
Over the past year, NTLA annual earnings before interest & taxes has changed by -$57.13 M (-12.47%)
What is Intellia Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of NTLA is -$144.77 M
What is the all time high quarterly EBIT for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly earnings before interest & taxes is -$1.20 M
What is Intellia Therapeutics quarterly EBIT year-on-year change?
Over the past year, NTLA quarterly earnings before interest & taxes has changed by -$13.66 M (-10.42%)
What is Intellia Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of NTLA is -$537.71 M
What is the all time high TTM EBIT for Intellia Therapeutics?
Intellia Therapeutics all-time high TTM earnings before interest & taxes is -$1.20 M
What is Intellia Therapeutics TTM EBIT year-on-year change?
Over the past year, NTLA TTM earnings before interest & taxes has changed by -$52.22 M (-10.76%)